Exome Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Exome Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Buy	+6,573	New	+$1.54M	1.08%	35
2024 Q4	–	Sell	-43,849	Closed	-$6.55M	–	65
2024 Q3	$6.55M	Buy	43,849 +23,849	+119%	+$3.22M	4.43%	2
2024 Q2	$2.73M	Buy	+20,000	New	+$2.72M	2.43%	17

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Exome Asset Management's ASND Position: Q2 2026 in Review

Exome Asset Management opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 6,573 shares worth $1.75M. The stake represents 1.08% of the portfolio and ranks #35 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in ASND as recently as Q3 2024.

Exome Asset Management first reported a position in ASND in Q2 2024 and has held it in 3 quarters since. The position peaked at $6.55M in Q3 2024. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Exome Asset Management held 6,573 shares of Ascendis Pharma A/S worth $1.75M as of Q2 2026.
Ascendis Pharma A/S was a new Exome Asset Management position in Q2 2026.
Ascendis Pharma A/S made up 1.08% of Exome Asset Management's portfolio in Q2 2026, its #35 holding.
Exome Asset Management first reported a position in Ascendis Pharma A/S in Q2 2024 and has held it in 3 quarters since.
Exome Asset Management's Ascendis Pharma A/S position peaked at $6.55M in Q3 2024.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.